Zobrazeno 1 - 10
of 34
pro vyhledávání: '"I-Ming L Chen"'
Autor:
Era L. Pogosova-Agadjanyan, Anna Moseley, Megan Othus, Frederick R. Appelbaum, Thomas R. Chauncey, I-Ming L. Chen, Harry P. Erba, John E. Godwin, Isaac C. Jenkins, Min Fang, Mike Huynh, Kenneth J. Kopecky, Alan F. List, Jasmine Naru, Jerald P. Radich, Emily Stevens, Brooke E. Willborg, Cheryl L. Willman, Brent L. Wood, Qing Zhang, Soheil Meshinchi, Derek L. Stirewalt
Publikováno v:
Biomarker Research, Vol 8, Iss 1, Pp 1-13 (2020)
Abstract Background The recently updated European LeukemiaNet risk stratification guidelines combine cytogenetic abnormalities and genetic mutations to provide the means to triage patients with acute myeloid leukemia for optimal therapies. Despite th
Externí odkaz:
https://doaj.org/article/066cab4547fe4d0eae3f37a2fba497cb
Autor:
Sarah K Tasian, Deborah S Hunter, I-Ming L Chen, Richard C Harvey, Andrew J. Carroll, Elizabeth Wagner, Shalini C Reshmi, Michael J Borowitz, Brent L. Wood, Jeannie Daniel, Meenakshi Devidas, Elizabeth A. Raetz, Stephen P. Hunger, Albert Assad, Mignon L. Loh
Publikováno v:
Blood. 140:6117-6118
Autor:
Qing Zhang, Kenneth J. Kopecky, Thomas R. Chauncey, Era L. Pogosova-Agadjanyan, John E. Godwin, Cheryl L. Willman, Jerald P. Radich, Emily A. Stevens, Frederick R. Appelbaum, Anna Moseley, Min Fang, I-Ming L. Chen, Megan Othus, Isaac C. Jenkins, Harry P. Erba, Soheil Meshinchi, Mike Huynh, Brent L. Wood, Alan F. List, Derek L. Stirewalt, Brooke E. Willborg, Jasmine Naru
Publikováno v:
Biomarker Research, Vol 8, Iss 1, Pp 1-13 (2020)
Biomarker Research
Biomarker Research
Background The recently updated European LeukemiaNet risk stratification guidelines combine cytogenetic abnormalities and genetic mutations to provide the means to triage patients with acute myeloid leukemia for optimal therapies. Despite the identif
Autor:
Carolyn A. Felix, Patrizia Porazzi, Joanne M. Hilden, James W Davenport, Sarah K. Tasian, Meenakshi Devidas, ZoAnn E. Dreyer, Shenghao Jin, I-Ming L. Chen, Alix E. Seif, Tiffaney Vincent, Andrew J. Carroll, Martin Carroll, Blaine W. Robinson, Karen A. Urtishak, David T. Teachey, Katherine L. B. Borden, Biljana Culjkovic-Kraljacic, Stephen P. Hunger, Li-San Wang, Jeffrey S. Barrett, Jonni S. Moore, Richard C. Harvey, Nyla A. Heerema, Cheryl L. Willman
Publikováno v:
Oncogene
The poor outcomes in infant acute lymphoblastic leukemia (ALL) necessitate new treatments. Here we discover that EIF4E protein is elevated in most cases of infant ALL and test EIF4E targeting by the repurposed antiviral agent ribavirin, which has ant
Autor:
Pogosova-Agadjanyan, Era L., Moseley, Anna, Othus, Megan, Appelbaum, Frederick R., Chauncey, Thomas R., I-Ming L. Chen, Erba, Harry P., Godwin, John E., Jenkins, Isaac C., Fang, Min, Huynh, Mike, Kopecky, Kenneth J., List, Alan F., Naru, Jasmine, Radich, Jerald P., Stevens, Emily, Willborg, Brooke E., Willman, Cheryl L., Wood, Brent L., Zhang, Qing, Meshinchi, Soheil, Stirewalt, Derek L.
Additional file 1: Table S1. Targeted Sequencing Details. Table S1A. Target regions for Wafergen Sequencing. Table S1B Primers and Amplicon Details for Wafergen Sequencing. Table S1C. Primers for CEBPA targeted MiSeq Assay. Table S2. Loci that Failed
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::243f8711220495b4dd0b9221b05cc944
Autor:
Frederick R. Appelbaum, Jerald P. Radich, John E. Godwin, Era L. Pogosova-Agadjanyan, Min Fang, I-Ming L. Chen, Derek L. Stirewalt, Cheryl L. Willman, Alan F. List, Kenneth J. Kopecky, Harry P. Erba, Thomas R. Chauncey, Brent L. Wood, Megan Othus, Anna Moseley, Galina Pogosov, Soheil Meshinchi
Publikováno v:
Biopreservation and Biobanking. 16:42-52
Current prognostic models for acute myeloid leukemia (AML) are inconsistent at predicting clinical outcomes for individual patients. Variability in the quality of specimens utilized for biomarker discovery and validation may contribute to this progno
Autor:
Alejandro Sweet-Cordero, Alex G. Lee, Stephanie M. Smith, Minyoung Youn, Nathan Sumarsono, I-Ming L. Chen, Henrique Bittencourt, Purvesh Khatri, Lara C. Murphy, Michele S. Redell, Hee-Don Chae, Todd A. Alonzo, Elizabeth Spiteri, Kathleen M. Sakamoto, Elizabeth A. Eklund, Min Huang, Kara L. Davis, Michele Donato, Norman J. Lacayo, Nobuko Hijiya, Parveen Abidi, Jairo Matthews, Ilana Galperin, Cecilia Fu, Gary V. Dahl, Jason Gotlib, Steven M. Kornblau, Jason Erdmann, Catherine Aftandilian
Publikováno v:
Blood. 138:1473-1473
Chronic myeloid leukemia (CML) accounts for 2-9% of leukemias in children and adolescents, and occurs with much greater frequency in adults. Compared to adults, children with CML tend to present with higher white blood cell counts and larger spleens,
Autor:
Natalie Delrocco, Mignon L. Loh, Michael Borowitz, Karen R Rabin, Patrick A Zweidler-McKay, Kelly W Maloney, Leonard A. Mattano, Eric C Larsen, Anne L Angiolillo, Reuven J Schore, Michael J. Burke, Wanda L Salzer, Brent L. Wood, Andrew J Carroll, Nyla A. Heerema, Shalini C Reshmi, Julie M Gastier-Foster, Richard C Harvey, I-Ming L Chen, Kathryn G Roberts, Charles G. Mullighan, Cheryl L Willman, Naomi J Winick, William L. Carroll, Stephen P. Hunger, Elizabeth A. Raetz, Meenakshi Devidas, John Kairalla
Publikováno v:
Blood. 138:2382-2382
Contemporary risk stratification algorithms commonly use threshold-defined categories of clinically relevant risk factors. The Children's Oncology Group (COG) uses National Cancer Institute (NCI) risk group (RG), cytogenetics, and early response to t
Autor:
Eric Larsen, Brent L. Wood, Reuven J. Schore, Shalini C. Reshmi, Kathryn G. Roberts, Nyla A. Heerema, Leonard A. Mattano, Michael J. Borowitz, Wanda L. Salzer, Richard C. Harvey, Elizabeth A. Raetz, John A. Kairalla, Stephen P. Hunger, Cheryl L. Willman, Julie M. Gastier-Foster, Andrew J. Carroll, Meenakshi Devidas, Charles G. Mullighan, Michael J. Burke, Patrick A. Zweidler-McKay, Kelly W. Maloney, Natalie DelRocco, Karen R. Rabin, Anne L. Angiolillo, Mignon L. Loh, Naomi J. Winick, William L. Carroll, I-Ming L. Chen
Publikováno v:
Blood. 136:39-40
Current risk stratification for COG ALL patients (pts) relies on National Cancer Institute (NCI) risk group (RG) at diagnosis, somatic genetics, and early response to therapy as measured by specific thresholds of minimal residual disease (MRD) using
Autor:
Reuven J. Schore, Michael J. Burke, Cheryl L. Willman, Zhiguo Chen, Mignon L. Loh, Julie M. Gastier-Foster, William L. Carroll, I-Ming L. Chen, Naomi J. Winick, Eric Larsen, Michael J. Borowitz, Brent L. Wood, Karen R. Rabin, Wanda L. Salzer, Richard C. Harvey, Johann K. Hitzler, Elizabeth A. Raetz, Anne L. Angiolillo, Kathryn G. Roberts, Nyla A. Heerema, Sarah K. Tasian, Yunfeng Dai, Andrew J. Carroll, Meenakshi Devidas, Charles G. Mullighan, Shalini C. Reshmi, Stephen P. Hunger, Kelly W. Maloney
Publikováno v:
Blood. 136:44-45
Background: Patients with Down syndrome (DS) have an approximately 10-fold increased risk of developing ALL, and the spectrum of genetic alterations differs from that of non-DS ALL. Rearrangement and/or overexpression of cytokine receptor-like factor